Find the PSMA antibody that fits your needs. Choose from 1 of 63 PSMA antibodies, which have been validated in experiments with 11 publications and 178 images featured in our data gallery. Browse primary antibodies for WB, Flow, IHC, ICC/IF, ELISA, IP, and other applications.

Prostate-specific membrane antigen (PSMA) is a type II membrane protein originally characterized by the murine monoclonal antibody (mAb) 7E11-C5.3 and is expressed in all forms of prostate tissue, including carcinoma. 1–6 The PSMA protein has a unique 3-part structure: a 19-amino-acid internal portion, a 24-amino-acid transmembrane portion, and ...

With the development of monoclonal antibodies (mAbs) against PSMA, cancer cells can be targeted effectively while minimizing side effects to patients. Radioactivity can be attached to mAbs for imaging and treatment.

There is now substantial evidence of the high sensitivity of PSMA-targeted imaging for PCa lesions and growing evidence of the therapeutic efficacy of PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

May 28, 2021 · This figure depicts the most meaningful PSMA-targeted therapies for prostate cancer, including radioligand therapy, antibody-drug conjugates, cellular immunotherapy, photodynamic therapy,...

Aug 23, 2022 · Patients with prostate-specific membrane antigen (PSMA)-positive tumors can benefit from PSMA-targeted therapy; thus, we have constructed a phage-displayed synthetic antibody library for the production of novel PSMA antibodies with superior PSMA-targeting ability, favoring clinical management.

Aug 11, 2021 · Here, we describe a unique semisynthetic bispecific antibody that uses site-specific unnatural amino acid conjugation to combine the potency of a T cell–recruiting anti-CD3 antibody with the specificity of an imaging ligand (DUPA) for prostate-specific membrane antigen.

ARX517, an Anti-Prostate-Specific Membrane Antigen (PSMA) Antibody-Drug Conjugate (ADC), Demonstrates Promising Safety and Efficacy in Heavily Pre-Treated Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sep 1, 2021 · Purpose of review: Targeting Prostate-Specific Membrane Antigen (PSMA) has paved the way for personalized medicine in prostate cancer (PCa) patients. This review aims to highlight the role of PSMA targeting antibodies in PCa, for diagnostic and therapeutic purposes.

Oct 23, 2023 · ARX517 is an investigational antibody-drug conjugate composed of a humanized anti-PSMA mAb linked to AS269, an Ambrx proprietary potent microtubule inhibitor. ARX517 is designed to target the prostate-specific membrane antigen (PSMA).